BETH ISRAEL DEACONESS MEDICAL CENTER

UCB's Bimzelx (bimekizumab-bkzx) approved by FDA for moderate-to-severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease affecting 1% of the US population, more common in women. Bimzelx, also approved for other autoimmune conditions, selectively binds to inflammatory cytokines, reducing HS symptoms by 50% within 16 weeks in phase 3 studies. Administered subcutaneously, it offers a new treatment option with common side effects including upper respiratory tract infections, oral candidiasis, and headache. List price is $7,552.80 per 1 mL, but insurance coverage can reduce costs significantly.

FDA approves bimekizumab for moderate to severe hidradenitis suppurativa, adding to its 5 US indications in 13 months, supported by BE HEARD trials and positive long-term data.

FDA approves UCB’s BIMZELX for moderate-to-severe hidradenitis suppurativa, targeting IL-17F and IL-17A, addressing unmet needs with deep and sustained clinical responses.

UCB announced FDA approval of bimekizumab-bkzx (Bimzelx) for moderate to severe hidradenitis suppurativa (HS), the first dual IL-17A and IL-17F inhibitor for HS. Clinical trials showed deep and sustained responses up to 48 weeks with a favorable safety profile, offering a novel treatment for this chronic condition.

FDA approves BIMZELX® (bimekizumab-bkzx) for moderate-to-severe hidradenitis suppurativa, supported by Phase 3 studies BE HEARD I and II showing improved signs and symptoms at Week 16, sustained to Week 48.

FDA approves BIMZELX® (bimekizumab-bkzx) for moderate to severe hidradenitis suppurativa (HS), supported by Phase 3 studies BE HEARD I and II showing significant symptom improvement vs. placebo at Week 16, sustained to Week 48. HS is a chronic, painful inflammatory skin disease with substantial unmet needs, marking the fifth indication for bimekizumab-bkzx in the U.S.

UCB announces FDA approval of BIMZELX® (bimekizumab-bkzx) for moderate to severe hidradenitis suppurativa (HS), the first medicine to selectively inhibit IL-17F and IL-17A. Phase 3 studies showed deep and sustained clinical responses up to 48 weeks, addressing substantial unmet needs in HS treatment.

UCB's Bimzelx (bimekizumab-bkzx) receives FDA approval as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa (HS). Bimzelx demonstrated deep and sustained clinical responses in Phase 3 studies, addressing significant unmet needs in HS treatment.

New analysis finds over 136 million U.S. adults could be candidates for GLP-1 drug semaglutide, used for diabetes, weight loss, and heart disease prevention, despite high costs and limited insurance coverage.

Echo IQ (ASX:EIQ) signed an integration agreement with top US cardiology hospital Beth Israel Deaconess Medical Center, leveraging its FDA-cleared AI-powered algorithm for heart disease detection. This deal, following FDA clearance, positions EIQ for significant industry exposure and potential revenue generation, with further hospital partnerships anticipated. EIQ's technology targets aortic stenosis and heart failure, with reimbursement from insurance companies forming its revenue model. The company is also in advanced negotiations with the prestigious Mayo Clinic for clinical validation of its heart failure product.